Ascendis moves forward with phase III drug
Ascendis Pharma has now reached the desired amount of patients for its phase III trial for the rare disease hypoparathyreoidism. The company has also achieved regulatory progress for the same drug in Japan.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Ascendis Pharma can be satisfied with the progress it has made on several fronts regarding its new drug candidate.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma starts study of eczema tablet for nettle rash
For subscribers
.jpg&w=384&q=75)
